Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 70

1.

Urinary ethyl glucuronide (uEtG) as a marker for alcohol consumption in liver transplant candidates: a real-world cohort.

Vollmar J, Stern F, Lackner K, Mildenberger P, Greif-Higer G, Mittler J, Darstein F, Foerster F, Grimm D, Marquardt JU, Schattenberg J, Woerns MA, Lang H, Galle PR, Zimmermann T.

Z Gastroenterol. 2020 Jan;58(1):30-38. doi: 10.1055/a-1008-9736. Epub 2020 Jan 13.

PMID:
31931538
2.

Sarcopenia as prognostic factor for survival after orthotopic liver transplantation.

Pinto Dos Santos D, Kloeckner R, Koch S, Hoppe-Lotichius M, Zöller D, Toenges G, Kremer WM, Zimmermann T, Mittler J, Lang H, Düber C, Galle PR, Weinmann A, Sprinzl MF.

Eur J Gastroenterol Hepatol. 2019 Nov 8. doi: 10.1097/MEG.0000000000001552. [Epub ahead of print]

PMID:
31725030
3.

Serum markers of type III and IV procollagen processing predict recurrence of fibrosis in liver transplanted patients.

Nielsen MJ, Villesen IF, Gudmann NS, Leeming DJ, Krag A, Karsdal MA, Zimmermann T, Schuppan D.

Sci Rep. 2019 Oct 16;9(1):14857. doi: 10.1038/s41598-019-51394-4.

4.

Long-term observation of hepatocellular carcinoma recurrence after liver transplantation at a European transplantation centre.

Foerster F, Hoppe-Lotichius M, Vollmar J, Marquardt JU, Weinmann A, Wörns MA, Otto G, Zimmermann T, Galle PR.

United European Gastroenterol J. 2019 Jul;7(6):838-849. doi: 10.1177/2050640619840221. Epub 2019 Mar 25.

5.

Deletion of organic cation transporter Oct3 promotes hepatic fibrosis via upregulation of TGFβ.

Vollmar J, Kim YO, Marquardt JU, Becker D, Galle PR, Schuppan D, Zimmermann T.

Am J Physiol Gastrointest Liver Physiol. 2019 Aug 1;317(2):G195-G202. doi: 10.1152/ajpgi.00088.2019. Epub 2019 Jun 26.

PMID:
31241979
6.

Evolution of HCV patient characteristics and DAA regimens in the German Hepatitis C Registry (DHC-R) in 2014 and 2015.

Sarrazin C, Buggisch P, Mauss S, Müller T, Zimmermann T, Klinker H, Pathil-Warth A, Schlag M, Nalpas C, Wegner S, Lonjon-Domanec I, Simon KG.

Z Gastroenterol. 2019 May;57(5):584-592. doi: 10.1055/a-0859-7561. Epub 2019 May 13.

PMID:
31083746
7.

Alcohol and Cannabis Consumption Does Not Diminish Cure Rates in a Real-World Cohort of Chronic Hepatitis C Virus Infected Patients on Opioid Substitution Therapy-Data From the German Hepatitis C-Registry (DHC-R).

Christensen S, Buggisch P, Mauss S, Böker KH, Müller T, Klinker H, Zimmermann T, Serfert Y, Weber B, Reimer J, Wedemeyer H; German Hepatitis C-Registry.

Subst Abuse. 2019 Mar 28;13:1178221819835847. doi: 10.1177/1178221819835847. eCollection 2019.

8.

Cirrhosis risk score of the donor organ predicts early fibrosis progression after liver transplantation.

Zimmermann A, Darstein F, Hoppe-Lotichius M, Toenges G, Lautem A, Abel F, Schad A, Mittler J, Vollmar J, Grimm D, Lang H, Galle PR, Zimmermann T, Schuppan D.

J Gastrointestin Liver Dis. 2019 Mar;28(1):53-61. doi: 10.15403/jgld.2014.1121.281.crr.

9.

Expression and prognostic significance of insulin‑like growth factor-2 receptor in human hepatocellular carcinoma and the influence of transarterial chemoembolization.

Lautem A, Simon F, Hoppe-Lotichius M, Mittler J, Vollmar J, Schad A, Düber C, Galle PR, Otto G, Zimmermann T, Lang H.

Oncol Rep. 2019 Apr;41(4):2299-2310. doi: 10.3892/or.2019.6995. Epub 2019 Feb 1.

PMID:
30720132
10.

[Chronic granulomatous disease as a rare differential diagnosis of inflammatory bowel disease].

Metzger JC, Kurz E, von Spee-Mayer C, Kolck G, Bogumil A, Galle PR, Zimmermann T.

Z Gastroenterol. 2018 Dec;56(12):1507-1512. doi: 10.1055/a-0732-5865. Epub 2018 Nov 22. German.

PMID:
30466133
11.

Clinical Predictors for Poor Quality of Life in Patients With Covert Hepatic Encephalopathy.

Labenz C, Toenges G, Schattenberg JM, Nagel M, Sprinzl MF, Nguyen-Tat M, Zimmermann T, Huber Y, Marquardt JU, Galle PR, Wörns MA.

J Clin Gastroenterol. 2019 Aug;53(7):e303-e307. doi: 10.1097/MCG.0000000000001149.

PMID:
30439761
12.

[Hepatitis C: Innovations in the last 10 years].

Pflaum J, Zimmermann T.

MMW Fortschr Med. 2018 Nov;160(Suppl 3):66-70. doi: 10.1007/s15006-018-1127-3. Review. German. No abstract available.

PMID:
30421192
13.

Estimation of liver fibrosis by noncommercial serum markers in comparison with transient elastography in patients with chronic hepatitis C virus infection receiving direct-acting antiviral treatment.

Knop V, Hofmann WP, Buggisch P, Klinker H, Mauss S, Günther R, Hinrichsen H, Hüppe D, Pfeiffer-Vornkahl H, Simon KG, Berg T, Manns MP, Friedrich-Rust M; German Hepatitis C-Registry.

J Viral Hepat. 2019 Feb;26(2):224-230. doi: 10.1111/jvh.13021. Epub 2018 Nov 8.

PMID:
30315694
14.

Hepatitis E virus genotype 3 is a common finding in liver-transplanted patients undergoing liver biopsy for elevated liver enzymes with a low De Ritis ratio and suspected acute rejection: A real-world cohort.

Darstein F, Häuser F, Straub BK, Wenzel JJ, Conradi R, Mittler J, Lang H, Galle PR, Zimmermann T.

Clin Transplant. 2018 Nov;32(11):e13411. doi: 10.1111/ctr.13411. Epub 2018 Oct 27.

PMID:
30230607
15.

Validation of the simplified Animal Naming Test as primary screening tool for the diagnosis of covert hepatic encephalopathy.

Labenz C, Beul L, Toenges G, Schattenberg JM, Nagel M, Sprinzl MF, Nguyen-Tat M, Zimmermann T, Huber Y, Marquardt JU, Galle PR, Wörns MA.

Eur J Intern Med. 2019 Feb;60:96-100. doi: 10.1016/j.ejim.2018.08.008. Epub 2018 Aug 19.

PMID:
30131209
16.

Progression of transthyretin (TTR) amyloidosis in donors and recipients after domino liver transplantation-a prospective single-center cohort study.

Vollmar J, Schmid JC, Hoppe-Lotichius M, Barreiros AP, Azizi M, Emrich T, Geber C, Schad A, Weyer V, Otto G, Heise M, Mittler J, Birklein F, Lang H, Galle PR, Zimmermann T.

Transpl Int. 2018 Nov;31(11):1207-1215. doi: 10.1111/tri.13326. Epub 2018 Aug 28.

17.

Impact of direct-acting antiviral therapy on the need for liver transplantation related to hepatitis C in Germany.

Herzer K, Gerken G, Kroy D, Tacke F, Plewe J, Eurich D, Spengler U, Strassburg CP, Welker MW, Pischke S, Sterneck M, Mehrabi A, Weiss KH, Herber A, Berg T, Zimmermann T, Galle PR, Heinzow H, Schmidt H, Markova A, Serfert Y, Manns MP, Zeuzem S, Wedemeyer H.

J Hepatol. 2018 Oct;69(4):982-984. doi: 10.1016/j.jhep.2018.07.001. Epub 2018 Aug 6. No abstract available.

PMID:
30089577
18.

Effectiveness and Safety of Direct-Acting Antiviral Combination Therapies for Treatment of Hepatitis C Virus in Elderly Patients: Results from the German Hepatitis C Registry.

Dultz G, Müller T, Petersen J, Mauss S, Zimmermann T, Muche M, Simon KG, Berg T, Zeuzem S, Hüppe D, Böker K, Wedemeyer H, Welzel TM; Leberstiftungs-GmbH Deutschland.

Drugs Aging. 2018 Sep;35(9):843-857. doi: 10.1007/s40266-018-0572-0.

PMID:
30084012
19.

Interferon- and ribavirin-free therapy with new direct acting antivirals (DAA) for chronic hepatitis C improves vascular endothelial function.

Schmidt FP, Zimmermann T, Wenz T, Schnorbus B, Ostad MA, Feist C, Grambihler A, Schattenberg JM, Sprinzl MF, Münzel T, Galle PR.

Int J Cardiol. 2018 Nov 15;271:296-300. doi: 10.1016/j.ijcard.2018.04.058. Epub 2018 Aug 1.

PMID:
30077529
20.

Clinical significance of detectable and quantifiable HCV RNA at the end of treatment with ledipasvir/sofosbuvir in GT1 patients.

Maasoumy B, Buggisch P, Mauss S, Boeker KHW, Müller T, Günther R, Zimmermann T, Manns MP, Sarrazin C, Hüppe D, Wedemeyer H, Vermehren J.

Liver Int. 2018 Nov;38(11):1906-1910. doi: 10.1111/liv.13932. Epub 2018 Aug 10.

PMID:
30022590

Supplemental Content

Loading ...
Support Center